| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C9289 | Asparaginase | Erwinaze | 1,000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Apr 4, 2012 | Dec 31, 2014 | No Longer Used | |
| J9019 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Jan 1, 2013 | Jan 1, 2026 | In Use | |
| J9042 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan 1, 2013 | In Use | ||
| C9287 | Brentuximab vedotin | Adcetris | 1 mg | Immunotherapy | Drug Antibody Conjugate | CD30 | No | 2011 | Jan 1, 2012 | Dec 31, 2012 | No Longer Used | |
| J1729 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 10 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2018 | In Use | |||
| NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Vandetanib | Caprelsa | 300 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
| J1726 | Hydroxyprogesterone Caproate | Makena | 10 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2018 | In Use | |||
| NA | Vandetanib | Caprelsa | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Abiraterone acetate | Zytiga | 250 mg | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Yes | 2011 | In Use | |||
| C9284 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jul 1, 2011 | Dec 31, 2011 | No Longer Used | |
| NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J9228 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jan 1, 2012 | In Use | ||
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J9196 | Gemcitabine HCl (Accord) | Gemcitabine | 200MG | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2011 | Mar 17, 2023 | In Use | ||
| NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
| J1725 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 1 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2012 | In Use | |||
| NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
| J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan 1, 2014 | In Use | ||
| NA | Carmustine wafer | Gliadel | 7.7mg | Chemotherapy | Alkylating Agent | Nitrosourea | No | 2012 | In Use | |||
| NA | Axitinib | Axitinib | 1 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
| J9306 | Pertuzumab | Perjeta | 1 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2012 | Jan 1, 2014 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home